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The tumor microenvironment (TME) is being increasingly recognized as a key factor in multiple stages of disease
progression, particularly local resistance, immune-escaping, and distant metastasis, thereby substantially impacting
the future development of frontline interventions in clinical oncology. An appropriate understanding of the TME
promotes evaluation and selection of candidate agents to control malignancies at both the primary sites as well as
the metastatic settings. This review presents a timely outline of research advances in TME biology and highlights
the prospect of targeting the TME as a critical strategy to overcome acquired resistance, prevent metastasis, and
improve therapeutic efficacy. As benign cells in TME niches actively modulate response of cancer cells to a broad
range of standard chemotherapies and targeted agents, cancer-oriented therapeutics should be combined with
TME-targeting treatments to achieve optimal clinical outcomes. Overall, a body of updated information is delivered
to summarize recently emerging and rapidly progressing aspects of TME studies, and to provide a significant
guideline for prospective development of personalized medicine, with the long term aim of providing a cure for
cancer patients.
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Cancer is a systemic disease, and it is not a solo production
but rather an ensemble performance [1]. Cancer cells act as
the leading devil, which is supported by a diverse cast of be-
nign cells in the surrounding milieu that actively facilitates
the malignant progression in a three-dimensional structure.
Even under therapeutic conditions, resistant cancer clones
frequently emerge and show complex dynamics with spatial
and temporal heterogeneity, implying distinct mechanisms
of resistance operative at different sites depending on treat-
ment selection pressure [2,3]. The disease is usually initi-
ated as a result of the stepwise accumulation of genetic and
epigenetic changes in the epithelial compartment; however,
increasing evidence indicates that the tumor microenviron-
ment (TME) can dictate aberrant tissue function and play
a critical role in the subsequent development of more
advanced and refractory malignancies [4]. Particularly,* Correspondence: sunyu@sibs.ac.cn
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unless otherwise stated.inappropriate activation of the stroma, including those
provoked by the therapeutics, immunomodulation medi-
ated by certain TME cell lineages, and distant metastasis
induced by the TME components, can potentiate and ac-
celerate tumor progression towards a high rate of disease
mortality [5].
Physiologically, the stroma in healthy individuals is a
physical barrier against tumorigenesis; however, neoplastic
cells elicit various changes to convert the adjacent TME
into a pathological entity. The orchestration of such an
event implicates migration of stromal cells, remodeling of
matrix, and expansion of vasculature [6]. Regional differ-
ences under selective pressures, including acidity and hyp-
oxia in the neoplasia, drastically influence its progression,
as do distinct environmental factors select for mutations
that engender survival and repopulation of cancer cells,
eventually creating tumor heterogeneity and causing treat-
ment difficulty [7]. In this review, we define the biological
landscapes of neoplastic cell extrinsic environment,
branded the TME, discuss therapeutic resistance that en-
gages multiple stromal cell types, and present clinical
challenges lying ahead which may be well taken byhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer therapy.
The TME is a pathologically active niche that
shapes tumor evolution
The structurally and functionally essential elements in
the stroma of a typical TME include fibroblasts, myofi-
broblasts, neuroendocrine cells, adipose cells, immune
and inflammatory cells, the blood and lymphatic vascu-
lar networks, and the extracellular matrix (ECM). The
naive stroma is a critical compartment in maintaining
physiological homeostasis of normal tissue, and recent
studies strengthened the concept that some stromal
components have anticancer activities by regulating im-
munosuppression and restraining carcinogenesis, which
is particularly the case of pancreatic ductal adenocarcin-
oma [8,9]. The ability of the stroma to suppress carcino-
genesis apparently correlates with organismal survival
and contribute to longevity. However, once transformed
to a tumor-associated neighbor by various stimuli, the
stroma-derived effect turns to be adverse and can signifi-
cantly promote cancer progression. Under such condi-
tions, the stromal cells co-evolve with the cancer cells by
being frequently educated, coopted, or modified by the
latter to synthesize a wide variety of cytokines, chemo-
kines, growth factors, and proteinases, together dramat-
ically accelerating disease progression [6]. Thus, normal
stroma possesses an inherent plasticity to respond rapidly
to neoplastic situations, and act in concert with the adja-
cent epithelium in eliciting the emergence of “reactive
stroma”. The active stroma of solid tumors is not only
composed of carcinoma-associated fibroblasts (CAFs) and
myofibroblasts, but characterized with remodeled matrix,
reprogrammed metabolism, activated transcription, and
altered synthesis of repair-associated proteins [10-12].
Further, the physical or biological protection provided by
the stromal part of the TME limits the effective delivery of
anticancer agents to tumor foci and represents a favorable
milieu that allows cancer cells to circumvent programmed
cell death triggered by cytotoxicity and to develop ac-
quired resistance as a preliminary step towards more ma-
lignant phenotypes.
Progression of organ-specific tumors is also reliant on in-
filtration of immune cells and occurrence of angiogenesis,
which generates a stash for cancer stem cells (CSCs) and
provides a complex signaling environment. CSCs, also
known as tumor-initiating cells, have been intensively ex-
plored within the recent decade. Many tumor types involve
CSCs in the TME milieu, which are characterized with the
potential to cause resistance against various cytotoxicities
due to intrinsic mechanisms, including genetic changes
and epigenetic alterations. Both CAFs and CSCs are impli-
cated in the TME-mediated signaling to remodel cancer
cells; for instance, CAFs express high levels of extracellularfactors including chemokine CXC motif ligand (CXCL)12,
chemokine CC motif ligand (CCL)2, CCL8, and insulin-
like growth factor binding protein 7, thereby forming an
inflammatory niche [13-15]. Further, CSCs are highly re-
sponsive to immune modulation, and an immune signature
is present in human prostate CD133+ CSCs, including
interleukin (IL)-6 and interferon-γ receptor 1 [16].
Under in vivo conditions both the innate and adaptive
immune systems influence homeostasis, in particular the
recruitment of immune cells into the tumor-adjacent milieu
is active and forms distinct immune contextures, thereby
exerting profound impacts on clinical outcome. For ex-
ample, T cell activation involves both positive and negative
checkpoint signals to finely tune responses to prevent ex-
cessive pathological changes [17,18]. The myeloid-derived
suppressor cell (MDSC) population which encompasses
immature dendritic cells, neutrophils, monocytes, and early
myeloid progenitors implicates tumor-initiated endocrine
signaling to the immune system through multiple chemo-
kines such as granulocyte-macrophage colony stimulating
factor [19,20]. Some immunosuppressive myeloid lineages
not only inhibit adaptive immunity, but promote angiogen-
esis through secretion of soluble molecules like vascular
endothelial growth factor (VEGF) A, basic fibroblast growth
factor (FGF), and transforming growth factor β (TGF-β)
[21]. Independent of T cell activities, B cells are able to
facilitate disease progression by fostering pro-tumoral in-
flammation [22]. Furthermore, type II tumor-associated
macrophages (TAMs) drastically affect tumorigenesis,
angiogenesis, and intravasation, and can prevent immune
attack by natural killer (NK) and T cells during tumor
development and after recovery from chemo- and/or
immunotherapy [23].
In addition to many in vitro studies that prove the com-
plex role of the TME cell lineages, experimental animal
models with genetically modified stroma further presented
convincing data of the biological importance of the TME.
Genetic alterations in stromal fibroblasts caused patholo-
gies in the adjacent glandular epithelium, as demonstrated
by FGF10 overexpression in a tissue recombination model
and TGF-β type II receptor conditional elimination in
transgenic mice [24,25]. Thus, signaling activities of a sin-
gle factor in fibroblasts can modulate the oncogenic po-
tential of nearby epithelia in selected tissues. A new study
even reported that p62 deficiency in the prostate stroma
results in deregulation of cellular redox through an
mTORC1/c-Myc pathway of glucose and amino acid me-
tabolism, and upregulation of stromal IL-6 through c-Myc
inactivation induces a hyper-inflammatory phenotype [11].
Simultaneously, an autocrine pathway promotes TGF-β
and the induction of a CAF phenotype, which further in-
creases epithelial invasion and tumorigenesis. As metabolic
reprogramming of the stroma can decisively influence the
tumorigenic potential of the epithelial compartment, this
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date of therapeutic targets.
The TME acts as a dominant force to modify
treatment responses
Therapeutic resistance remains a major problem in clin-
ical oncology. In addition to fueling de novo tumorigen-
esis, a permissive TME modifies treatment responses by
affecting cell sensitivity to anticancer agents. The TME-
induced resistance to interventions applied for multiple
tumor types, as well as its magnitude, varies depending
on the cancer cells, stroma properties, and therapeutic
regimens. Further, drug resistance mediated by the TME
is not limited to classical agents such as those adminis-
tered in genotoxic chemotherapies; rather, it covers di-
verse pharmaceuticals including targeted agents [26].
Recent studies intensively evaluated the functional roles of
TME in protecting acute myeloid leukemia cells or chronic
lymphocytic leukemia cells against alkylating agents,
anthracyclines, imatinib and nucleoside analogues, mu-
tant Janus kinase 2 (JAK2) cells against JAK inhibitors
including tofacitinib and ruxolitinib, solid tumors such
as lung, colorectal, and head and neck malignancies against
erlotinib and cetuximab, as well as, more recently, mela-
noma against RAF inhibitors like vemurafenib [27-29].
TME-mediated resistance can be initiated by multiple
cell lineages and structural components in the stroma,
including but not limited to fibroblasts, endothelial
cells, pericytes, smooth muscle cells, neutrophils, ma-
crophages, integrins, fibronectins, and collagens [26,30].
Although numerous reports elaborated the biological
role of TME-derived factors in tumor growth or metasta-
sis, relatively few have delineated the impact of an agent-
activated TME to the therapeutic outcome. Recent studies
using targeted drugs or conventional chemotherapeutics
have filled the gaps to show that treatment-induced alter-
ations to the microenvironment can generate a protective
niche or shielding reservoir for the remnant cancer cell
population, which is termed minimal residual disease as
the occult site to prime tumor relapse [31]. Particularly,
resistance to chemotherapy frequently results from cell
extrinsic factors such as cytokines, growth factors, and
even proteases derived from a TME that is structurally
and functionally modified by drug-induced cytotoxicity
[32-34]. In such cases, CSCs represent the potential source
of eventual tumor relapse following therapy, which are typ-
ically therapy-resistant due to decreased oxidative stress
response, increased genomic stability, and expression of
multiple drug resistance transporters [35].
TME-exerted protection for cancer cells apply to mul-
tiple therapeutic situations. Upon melanoma treatment
by mitogen activated protein kinase (MAPK) pathway
inhibitors, TAMs expand and release tumor necrosis fac-
tor (TNF)-α as a crucial growth factor that providesresistance to the targeted therapy through the microphthal-
mia transcription factor [36]. Inhibiting TNF-α signaling
with IκB kinase inhibitors profoundly enhanced the efficacy
of MAPK pathway suppression by targeting not only the
melanoma cells but the microenvironment. In experiments
using doxorubicin to treat the well-established Eμ-Myc
model of Burkitt’s lymphoma, surviving metastatic cancer
cells were localized in the thymus [37]. Damage response
analyses in different lymphoid tissues and the derived cell
types revealed that thymic endothelial cells selectively se-
creted IL-6 and Timp-1 as prosurvival factors, both sig-
nificantly enhancing resistance of lymphoma. Interestingly,
inhibition of these factors or the upstream signaling path-
way mediated by p38 mitogen-activated protein kinase
(p38MAPK) increased the subsequent chemotherapeutic
efficacy. Similarly, a genome-wide study of transcriptional
responses of prostate stromal cells to genotoxic stress
uncovered a spectrum of soluble proteins topped by
WNT16B, a novel TME effector generated by the DNA
damage secretory program [38]. Expression of WNT16B
is regulated by NF-kB after DNA damage and subse-
quently activates the canonical Wnt pathway in adjacent
cancer epithelial cells, thus markedly attenuating the ef-
fects of cytotoxic chemotherapy [39]. Further, chemother-
apeutic agents to breast cancer trigger a parallel stromal
reaction represented by TNF-α production in endothelial
cells, which heightens the CXCL1/2 expression of cancer
cells via the NF-kB complex, eventually amplifying a
CXCL1/2-S100A8/9 loop and inducing chemoresistance
[40]. Collectively, the results present a mechanism by
which genotoxic therapies or targeted agents given in a
cyclical manner can enhance subsequent treatment resist-
ance through cell non-autonomous programs that are at-
tributed to the “treatment-activated TME” [26] (Table 1).
Although dominant anticancer regimens, including
chemotherapy and targeted therapy, provide major op-
tions for cancer patients, so far, mounting data pinpoints
to an intricate link between epithelial-mesenchymal tran-
sition (EMT) and therapeutic resistance. Gain of function
as resistance for cancer cells can be regulated by diverse
mechanisms, and it may arise as a direct consequence of
EMT triggered by a large array of the TME-derived mole-
cules through activation of intracellular networks that
cover hepatocyte growth factor/c-met, epidermal growth
factor (EGF)/EGF receptor (EGFR), Wnt/beta-catenin
axes, and several cytokine/chemokine-mediated pathways
such as TGF-β/Smad signaling [47-51]. In this regard,
most treatment-resistant cancers harbor a subgroup of
cells with stem-like or mesenchymal features that are
resistant to cancer therapies [52].
TME-conferred resistance is not limited to solid tumors.
A new study of leukemia identified a therapy-induced
niche in the bone marrow, which empowers the resident
leukemia propagating cells (LPCs) to survive with
Table 1 Some anticancer treatments are subject to acquired resistance provoked by stromal factors derived from the
disease-supporting TME
Therapeutics Cancer type Targeting mechanism Resistance mechanism Reference
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Prostate cancer Interrupt microtubule depolymerisation/
disassembly; generates DNA strand
breaks, inhibit topoisomerase II
Stroma-induced resistance through
secretion of multiple soluble factors,
with WNT16B as a major contributor
[39]
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receptor (EGFR), can stimulate apoptosis
and differentiation of cancer cell that
lack EGFR
Substantial stroma-induced resistance;
clinical responses to EGFR tyrosine kinase
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now tempered by the increasing number
of de novo and acquired resistance mechanisms,







Irreversibly inhibits EGFR and HER2 kinases Stromal expression of fibroblast growth factor
(FGF) 2 and the FGFR1 is upregulated, allowing
survival of afatinib-resistant cancer cells
[46]
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bine and/or daunorubicin, the first-line chemotherapeutic
agents for acute lymphoblastic leukemia patients, a pro-
tective TME was formed within the bone marrow. The
niche was morphologically volatile and changed dynamic-
ally, beginning as transient Nestin + cells, maturing by
switching to alpha small muscle actin cells, and ending as
fiber residues. Emergence of such an evolving TME signifi-
cantly contributes to treatment failure and precludes
complete remission. Given that genetic or epigenetic
reprogramming of niche-resident LPCs may occur to gen-
erate refractory subclones upon exposure to clinical treat-
ments [54], the study highlights that future therapeuticstrategies should be adjusted to prevent the arising of an
early protective TME. Given a scenario of agents that tar-
get various TME cell lineages, one can envisage that com-
binatorial therapies provide an effective solution which
both confines cancer cell progression and suppresses
TME-associated activities.
Tumor promotion by mesenchymal stem cells
(MSCs) and regulatory T cells (Tregs) in the TME
Throughout the course of tumor evolution, a vast group
of host cells, ranging from fibroblasts to macrophages,
sustain a supportive TME for disease progression, specif-
ically by interfering immunosurveillance against cancer
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several subpopulations are virtually bone marrow-
derived cells (BMDCs) and frequently implicated in
tumor expansion via homing to the primary site as active
components of the local TME. Being a typical represen-
tative of BMDCs but still keeping differentiation poten-
tial, MSCs mainly derive from the bone marrow but are
indeed resident in virtually all organs and mature tissues,
receiving much interest in recent years particularly in
cancer biology. In contrast to TAMs, which compose a
terminal lineage, MSCs remain primitive and can gener-
ate adipocytes, pericytes, chondrocytes, neurons, osteo-
cytes, and mainstay stromal cells, including fibroblasts
and endothelial cells, and can also transdifferentiate into
both ectodermal and endodermal cells, thereby display-
ing a high plasticity and contributing to tissue regener-
ation [56-59]. MSCs migrate towards the tumor site and
become a major component of tumor-adjacent stroma.
Approximately 20% of CAFs originate from bone mar-
row and derive from MSCs, as demonstrated by studies
using mouse models of inflammation-induced tumors
[60]. Tumors employ various strategies to recruit MSCs
and chemokines are the most reported; for instance,
breast tumors secret monocyte chemotactic protein-1 to
stimulate the migration of MSCs, while prostate tumors
release CXCL16 to attract MSCs via binding to the
CXCR receptor on these cells [43,61]. Once relocated to
the tumor site, MSCs actively communicate with several
cell types, including cancer cells and nearby immune
cells, thus being biologically involved in the regulation of
tumor development. Specifically, MSCs have intrinsic
clinical value and hold potential for therapeutic use in
stem cell-based cancer therapy as a vehicle to deliver
gene products to targeted sites [62-64].
MSCs are capable of modulating immune status;
however, the immunoregulatory function of MSCs is
not intrinsic but depends on their cytokine milieu [65].
MSCs isolated from spontaneous lymphomas have a
strikingly high expression of CCL2 compared with bone
marrow-derived MSCs (BM-MSCs), and promote tumor
growth by recruiting type 2 like TAMs to tumor site, a
phenomenon that can be mimicked by treating BM-MSCs
with tumor necrosis factor alpha (TNF-α) [66]. Combin-
ation treatment of MSCs with interferon gamma (IFN-γ)
and TNF-α would dramatically increase the expression of
several chemokines and inducible nitric oxide synthase
(iNOS), a key immune suppressive molecule [67]. Further,
the immunosuppressive effect of MSCs induced by IFN-γ
and TNF-α can be dramatically enhanced by IL-17, which
enhances mRNA stability by modulating the protein level
of ARE/poly(U)-binding/degradation factor 1, a well-
known factor that promotes mRNA decay [68]. T cell
migration is driven by chemokines into proximity with
MSCs, where T cell responsiveness is suppressed by nitricoxide (NO). The MSC-mediated immunosuppression may
interfere with the anti-tumor immunity and help the
tumor escape immunological surveillance. Interestingly,
MSCs derived from p53-deficient mice express more
iNOS and exhibited greater immunosuppressive capacity
in the presence of inflammatory cytokines. When inocu-
lated with B16F0 melanoma in mice, p53-deficient
MSCs resulted in tumors larger than those harboring
wild type MSCs, and such a tumor promoting effect
could be abolished by administration of the iNOS in-
hibitor, S-methylisothiourea [69]. However, information
collected from studies of the murine system may not be
directly extended to humans because human MSCs uti-
lized indoleamine 2,3-dioxygenase (IDO) instead of
iNOS to suppress immune response [70]. Therefore, a
recent study employed a humanized MSC system,
which allows mouse iNOS promoter-driven IDO ex-
pression to be activated by inflammatory cytokines
similar to the human IDO promoter [71]. Interestingly,
humanized MSCs reduced the tumor-infiltrating CD8+
T cells and B cells when co-injected with tumor cells in
mice, thus promoting tumor growth, highlighting the
important interaction between MSCs and other compo-
nents of the TME as well as the possibility of restoring
tumor immunity in humans by therapeutic targeting
IDO activity. Tumor-resident MSCs seem to be patho-
logically educated to favor tumor growth; inflammatory
cytokines may act as a major driver for the change of
local microenvironments, but other factors are also
likely to be implicated in TME-exerted modifications.
As supporting evidence, several studies demonstrated that
exosomes derived from BM-MSCs can induce progenitor
cells to undergo mesenchymal-to-epithelial transition
(MET), indicating active message delivery between cancer
cells and the bone marrow TME [72,73].
Of note, growth factors and cytokines released by MSCs
invoke proliferative signaling of cancer cells and protect
them against cell death, a function that can be exerted
passively. Chemotherapy to leukemia elicits resistance by
rebuilding an microenvironmental niche that allows cancer-
propagating cells to evade apoptosis, and MSCs generate
replatable mesenspheres and express CD29, CD51, and
chemokine receptor CCR1 [47]. In ovarian cancer, MSC
secretions promote phosphatidylinositol 3-kinase (PI3K)/
Akt signaling and the X-linked inhibitor of apoptosis pro-
tein phosphorylation, inducing carboplatin-specific re-
sistance through trogocytosis [74]. Interestingly, MSCs
can also release two distinct polyunsaturated fatty acids,
12-oxo-5,8,10-heptadecatrienoic acid and hexadeca-
4,7,10,13-tetraenoic acid, which are in minute quantities
but induce resistance to a broad spectrum of chemothera-
peutic agents, particularly platinum analogs [75].
The contribution of MSCs to tumor progression and
resistance is well established, while the MSC-mediated
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attracted increasing interest. In particular, human
leukocyte antigen-G5 secreted by MSCs stimulates
FoxP3+ CD25Hi CD4+ Tregs proliferation and main-
tains the immunosuppressive activity by reducing T lym-
phocytes and NK functions for an extended period upon
co-culture in vitro [76,77]. Tregs maintain immune toler-
ance and prevent inflammation by restraining the activity
of cytotoxic T cells and the proliferation of effector T cells,
correlating with poor prognosis in cancer patients. Deple-
tion of Tregs inhibits the progression of breast cancer,
leukemia, myeloma, fibrosarcoma, colon adenocarcinoma,
and lung cancer, while primary tumor infiltration by Tregs
promotes the metastatic potential [55].
The TME is an essential determinant of the
metastatic cascade
Metastasis accounts for approximately 90% of overall
mortality among solid tumor patients [78]. The metastatic
journey of cancer cells from original site to distant organs
comprises several distinct stages, including local invasion,
intravasation, circulationary survival, extravasation, and
ectopic recolonization. Tumors not only preferentially
select proclivity sites for metastasis, but exhibit variable
dormancy length in temporary course [31], both as im-
portant facets to be considered for improved drug design
and treatment strategy to thwart disease exacerbation at
each individual stage. A supporting TME allows stromal
cells to co-evolve with cancer cells, promoting the initial
dissemination and subsequent invasion at the primary site
and creating a permissive niche at the distant location.
The microenvironments in metastatic lesions differ prom-
inently from those of primary foci, and the formation of a
receptive TME before the arrival of disseminated tumor
cells enhances metastatic efficiency, substantiating the
‘seed and soil’ hypothesis raised by Paget in the 19th
century [79,80].
Local invasion is the physical entry of cancer cells resi-
dent within a well-confined primary tumor into the sur-
rounding stroma. Cancer cells first breach the basement
membrane, a specialized ECM structure in the TME, by
co-opting the EMT program, which allows dissolution of
tight junctions, loss of cell polarity, and acquisition of mul-
tiple mesenchymal attributes [81]. Stromal cells further
enhance the aggressive behaviors of cancer cells through
various types of signaling. For instance, breast cancer inva-
siveness can be stimulated by IL-6 secreted from adipocytes
or promoted through EGFR-mediated signaling upon acti-
vation by TAMs that are subject to CD4+ T-lymphocyte in-
stigation in the local microenvironment [78]. Thus, TME at
primary site increases tumor dispersion via paracrine sig-
nals by generating a chemotactic relay system, a case that
can be further exemplified by CXCL14 secreted by CAFs,
or EGF and CXCL5 released by tumor-associated dendriticcells in prostate and lung tumors, respectively [82,83]. In
addition, TME-associated hypoxia or inflammation causes
tumor dissemination through multiple mechanisms, includ-
ing the NO-dependent VEGF upregulation mediated by
hypoxia-inducible factor 1α in endothelial cells [84] and
hypoxia-recruited infiltration of BMDCs including MDSCs
and NKs into secondary organs [85], each case remarkably
promoting pre-metastatic dissemination in the primary
organ.
Intravasation is a critical step that allows cancer cells to
cross pericyte and endothelial cell barriers before they gain
access to other organs [86,87]. For example, CDC42-
mediated expression of integrin β1 supports the interplay
of lung cancer cells with endothelium and thus promotes
transendothelial migration, while TGF-β enhances breast
cancer intravasation by increasing cancer cell penetration
through microvessel walls [87,88]. Conversely, the tran-
scriptional modulator amino-terminal enhancer of split
blocks intravasation in colon cancer through Notch-
dependent mechanisms [86]. Resembling the stromal
lineages, cancer cells can also enhance vasculature per-
meability, particularly at the site of extravasation where
normal endothelial cells are tightly organized, to gain
transendothelial entrance by secreting factors including
angiopoietin 1, angiopoietin-like 4, cytochrome c oxi-
dase subunit 2, epiregulin, matrix metalloproteinase
(MMP)-1/2/3/10, TGF-β, and VEGF in the case of lung
or brain carcinoma [31].
Either at primary sites or in vasculature vessels, cancer
cells can release microvesicles or soluble factors to adapt
incipient metastatic sites into ‘pre-metastatic niches’; for
example, systemic factors attract bone marrow-derived
macrophages and hematopoietic progenitor cells that are
accompanied by CAFs and endothelial cells to remodel
tissue and eventually cause lung metastasis [89]. How-
ever, metastasis-incompetent cancer cells can foster a
metastasis-compatible TME by secreting extracellular
factors including thrombospondin 1 to promote niche
formation at metastatic sites [90]. Successful seeding of
cancer cells at secondary organs is just a prerequisite,
and the TME at the secondary site may actually restrain
ectopic cell survival and expansion as illustrated by
neutrophil-mediated killing of cancer cells or thrombos-
pondin 1 secretion by bone marrow-derived Gr1+ cells
[90,91]. Interestingly, cancer cells can manage to evade ini-
tial cell-eliminating defense activities at distant sites and
enter dormancy as micrometastases for a certain period
before evident expansion or disease relapse. Tumor dor-
mancy is regulated by several mechanisms, driven partially
by the TME, including cellular dormancy (cells arrested in
G0), tumor mass dormancy (proliferation refrained by
apoptosis), or immune dormancy (an equilibrium main-
tained by immunosurveillance) [92]. Unfortunately, tumors
are prone to be awakened by various stimuli such as
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stability, which allow them to exit dormancy for resumed
metastatic progression, while more events of tumor awak-
ening and distant outgrowth are driven by the TME
constituents. A novel mechanism of triple-negative breast
cancer metastasis was recently delineated, and involves the
TME factors as peripheral signals, including EGF and
insulin-like growth factor-I (IGF-I), at distant indolent
tumor sites [93]. Bioavailability of EGF and IGF-I increases
the expression of transcription factors associated with plur-
ipotency, proliferation, and phenotypic transition, whereas
combinatorial therapy to target EGF and IGF-I signaling
prevents metastatic growth, suggesting that plasticity
and recurrence rates can be dictated by host systemic
factors and offer remarkable therapeutic potential for
triple-negative breast cancer patients.
Micro RNAs (miRNAs) are circulated in cancer patient
serum and can serve as important biomarkers for many
cancer types [94]. New studies presented mechanistic evi-
dence that some miRNAs directly regulate metastasis by
mediating tumor–TME interactions. Particularly, miR-210
is released from metastatic breast cancer cells via nSMase2-
dependent exosomal secretion, which once transported to
endothelial cells can enhance cell migration and capillary
formation, thereby enhancing angiogenesis and metastasis
[95]. The miRNAs can also be transmitted from stroma
cells to cancer cells as exemplified by microvesicle-
delivered miR-223, which is highly expressed in IL-4-
activated TAMs but not in breast cancer cells and which,
upon transmission from TAMs to cocultured cancer cells,
promotes tumor invasion and metastasis [96]. The trans-
mission of miRNAs between different cell types provides
an additional mechanism of TME-regulated metastasis.
Altogether, it is increasingly evident that distinct stages
of tumor advancing are subject to continuous and com-
prehensive influence of the TME in a special and temporal
manner, underscoring the necessity to consider the TME
in the context of clinical management (Figure 1).
Therapeutic strategies to manipulate the TME
with acumen
Innate resistance to clinical therapeutics is a hallmark of
cancer; however, acquired resistance has also emerged as
a daunting challenge to anticancer treatments by minim-
izing the efficacy of otherwise successful regimens. The
vast majority of mainstay therapeutic strategies against
human tumors are designed to target intrinsic traits of
cancer cells. In contrast, stromal cells within the TME
are generally stable in genetics and/or epigenetics and
thus less likely to be susceptible to diverse mechanisms
of therapeutic resistance. Further, given the accumulating
evidence of overwhelming heterogeneity at each aspect of
tumor evolution which is significantly subject to func-
tional influence of cancer cell extrinsic compartments,targeting the TME turns out to be quite urgent and should
be given enough priority [97-99].
In the tumor, continuous interactions between cancer
cells and the surrounding TME actively occur via direct
intercellular contact or through secreted signaling mol-
ecules. To date, a handful of targeted therapeutics against
specific stromal compartments is successfully implemented,
which shows decent promise in substantially minimizing
pathological contributions of the TME in clinical settings
(Table 2). Based on the growing data from clinical develop-
ment and relevant trials, however, some anticancer drugs
failed to show convincing benefits. For example, a group of
pan-protease inhibitors, such as marimastat, tanomastat,
and prinomastat, could not deliver significant therapeutic
advantage over standard-of-care treatments, possibly due to
the fact that MMP activities are more closely correlated
with early stage tumors rather than late-stage malignancies
[6]. Moreover, although mounting preclinical studies sub-
stantiated enhanced expression of Hedgehog ligands across
multiple forms of cancer and associated stromal fibroblast
activation, suppressors against the major Hedgehog path-
way protein Smoothened, mainly vismodegib and saridegib,
were unable to prove their efficacy except some limited and
transient responses [100,101].
To date, the mainstay of therapeutic strategies that target
the TME in vivo has established translational avenues and
paved the road for continued inputs into clinical frontiers.
Despite the preliminary success of TME-targeted therapies,
there remain several important issues that must be clearly
addressed. Conventional anticancer treatments frequently
cause structural and functional alterations of the TME,
which contribute to acquired resistance and severely
compromise clinical outcomes by generation of cancer-
protective niches, emphasizing the necessity to consider
the global TME response in future clinical intervention.
First, novel biomarkers that indicate the treatment conse-
quence and image the extent of TME damage through
examination of patient bio-specimens (particularly serum
samples) will allow for real time surveillance, therapeutic
regimen optimization, and drug design innovation – each
case is eagerly desired. Identification and selection of these
molecules to establish a diagnostic panel applicable to
clinical conditions would significantly accelerate the ad-
vancement of translational medicine. Second, the TME-
stimulated cancer resistance and disease resilience may be
technically prevented by rational administration of agents
between therapeutic cycles to periodically retard key regu-
lators of the TME signaling network, a feasible approach
to minimize the influence of tumor-promoting factors
from activated stromal cells that either develop a secretory
phenotype or exert other adverse actions to enhance path-
ologies [5,102]. Third, MSCs are currently being tested in
clinical trials for the treatment of various diseases owing
to their potential and ability to differentiate into various
Figure 1 Cancer develops in a complex and dynamic TME, which exerts profound impacts to disease progression. Cancer cells are in
close relationship with diverse non-cancer cell types within the TME, forming a functional nexus that facilitates tumor initiation, survival, and exacerbation.
Cytotoxicity generated by treatments including chemotherapy, radiation, and targeted therapy eliminates many malignant cells within the cancer cell
population; however, surviving cells are frequently retained in specific TME niches. Such protection minimizes the sensitivity to anti-cancer agents and
generates resistant subclones through distinct mechanisms, prominently through acquired resistance conferred by a large body of soluble
factors released from damaged or remodeled stroma. Alternatively, BMDCs, including MSCs and Tregs, mediate immunomodulation and
prevent inflammation by restraining the activity of cytotoxic T cells, correlating with poor prognosis. Either acquired resistance or immunosurveillance
evasion promotes cancer cell survival and subsequent expansion, allowing development of more advanced phenotypes, including tumor relapse,
distant metastasis, and therapeutic failure, eventually causing high mortality in clinical settings. CAF, Carcinoma-associated fibroblast; MSC,
Mesenchymal stem cell; BMDC, Bone marrow-derived cell; Treg cell, Regulatory T cell; EC, Endothelial cell; ECM, Extracellular matrix; TAM,
Tumor-associated macrophage.
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eration medicine. However, immunosuppressive and pro-
metastatic activities mediated by MSCs far outweigh their
stemness-derived benefits, particularly in the case of can-
cer. Thus, the caveat is, although normal MSCs are crucial
in wound healing and tissue remodeling, prospective ther-
apies restraining tumor-associated MSCs hold the promise
to improve the overall outcome of anticancer treatments.
To this end, identification of biomarkers expressed bysuch a special subset of MSCs presents a new task before
relevant targeting is available. Further understanding
the nature and mechanisms of stromal cells, particularly
BMDCs, in the physiological and malignant contexts will
pave the road for new therapies against deleterious com-
ponents of the TME, especially the immune-interfering
partners. Last but not least, successful preclinical evalu-
ation of combination therapies that target both tumor and
adjacent TME requires inputs from effective experimental
Table 2 A representative panel of therapeutic agents that target specific compartments of TME, an occult culprit
hiding in the backdrop of pathologies
Molecule Target Molecular type Company Status
ECM/fibroblasts
Sonidegib SMO Small molecule Novartis Phase II (NCT01708174, NCT01757327, NCT02195973)
Vasculature
Bevacizumab VEGFA Antibody Genentech/Roche FDA-approved ((BLA) 125085)
Vandetanib VEGFRs, PDGFRs, EGFR Small molecule AstraZeneca FDA-approved ((NDA) 022405)
Sunitinib VEGFRs, PDGFRs, FLT3, CSF1R Small molecule Pfizer FDA-approved ((NDA) 021938)
Axitinib VEGFRs, PDGFRs, KIT Small molecule Pfizer FDA-approved ((NDA) 022324)
Sorafenib VEGFRs, RAF PDGFRs, KIT Small molecule Bayer FDA-approved ((NDA) 021923)
Pazopanib VEGFRs, PDGFRs, KIT Small molecule GlaxoSmithKline FDA-approved ((NDA) 022465)
Cabozantinib VEGFR2, RETMET Small molecule Exelixis FDA-approved ((NDA) 023756)
Ziv-aflibercept VEGFA, VEGFB, PIGF Receptor-Fc fusion Regeneron FDA-approved ((BLA) 125418)
AMG-386 ANG2 RP-Fc fusion protein Amgen Phase III (NCT01204749, NCT01493505, NCT01281254)
Parsatuzumab EGFL-7 Antibody Genentech/Roche Phase II (NCT01399684, NCT01366131)
Enoticumab DLL4 Antibody Regeneron Phase I (NCT00871559)
Demcizumab DLL4 Antibody OncoMed Phase I (NCT00744562, NCT01189968, NCT01189942,
NCT01189929)
Nesvacumab ANG2 Antibody Regeneron Phase I (NCT01688960, NCT01271972)
Immune
Ipilimumab CTLA-4 Antibody Bristol-Myers Squibb FDA-approved ((BLA) 125377)
Sipuleucel-T PAP DC vaccine Dendreon FDA-approved ((BLA) 125197)
Aldesleukin IL-2 RP Prometheus FDA-approved ((BLA) 103293)
IFN-α-2b IFN-α receptor RP Merck FDA-approved ((BLA) 103132)
MK-3475 PD1 Antibody Merck Phase III (NCT01866319)
Nivolumab PD1 Antibody Bristol-Myers Squibb Phase III (NCT01642004, NCT01668784, NCT01673867,
NCT01721746, NCT01721772, NCT01844505)
Nivolumab OX40 Antibody Bristol-Myers Squibb and PPMC Phase III (NCT01642004, NCT01668784, NCT01673867,
NCT01721746, NCT01721772, NCT01844505)
MPDL-3280A PDL1 Antibody Genentech/Roche Phase II (NCT01846416)
PLX-3397 KIT, CSF1R, FLT3 Small molecule Plexxikon Phase II (NCT01349036)
BMS-663513 CD137 (4-1BB) Antibody Bristol-Myers Squibb Phase II (NCT00612664)
Blinatumomab CD3 and CD19 Bi-specific scFv Amgen Phase II (NCT01741792, NCT01466179, NCT01207388,
NCT01471782, NCT00560794, NCT01209286)
AMG-820 CSF1R Antibody Amgen Phase I (NCT01444404)
AMP-224 PD1 Antibody GlaxoSmithKline Phase I (NCT01352884)
TRX-518 GITR Antibody GITR, Inc. Phase I (NCT01239134)
IMC-CS4 CSR1R Antibody ImClone/Eli Lilly Phase I (NCT01346358)
CP-870,893 CD40 Antibody Pfizer Phase I (NCT00711191, NCT01008527, NCT00607048,
NCT01456585, NCT01103635)
References listed in the status column pertain to the molecule as a TME-modifying agent, either the FDA application, where approved, or the national clinical trial
identification of the oncology trial in the latest phase is listed (note that in some cases the drug may also be tested or approved for an indication for which it acts
directly on the tumor cell compartment, which will not be referenced here). ANG2, Angiopoietin 2; BLA, Biological license application; CD40, Cluster of differentiation antigen
40; CD137, Cluster of differentiation antigen 137; CSF1R, Colony stimulating factor 1 receptor; CTLA-4, Cytotoxic T-lymphocyte-associated antigen 4; DC, Dendritic cell; DLL4,
Delta-like 4; ECM, Extracellular matrix; EGFL-7, Epidermal growth factor like 7; EGFR, Epidermal growth factor receptor; Fc, Fragment, crystallizable; FDA, Food and Drug
Administration; FLT3, Fms-like tyrosine kinase 3; GITR, Glucocorticoid-induced TNFR-related; IFN, Interferon; IL-2, Interleukin 2;KIT, Stem cell factor receptor;
MET, Hepatocyte growth factor receptor; NCT, National clinical trial; NDA, New drug application; OX40, Cluster of differentiation antigen 134; PAP, Prostatic acid
phosphatase; PD-1, Programmed death-1; PDGFR, Platelet-derived growth factor receptor; PDL1, Programmed death ligand 1; PIGF, Phosphatidylinositol-glycan biosynthesis
class F protein; PPMC, Portland Providence Medical Center; RAF, Rapidly accelerated fibrosarcoma; RET, Rearranged during transfection; RP, Recombinant peptide; scFv,
Single-chain Fv; SMO, Smoothened; VEGF, Vascular endothelial growth factor; VEGFR, Vascular endothelial growth factor receptor. Table adapted from reference [6] of
this article (Junttila and de Sauvage) with permission from Nature, copyright 2013. Note, agents that either failed to be effective in clinical trials or have been officially
terminated are removed from the current list.
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major difficulty as specific elements of a typical TME,
such as immune cells and vasculature, cannot be easily in-
tegrated. The recently emerging model of patient-derived
xenograft reflects the complexity of tumors including the
structural and functional heterogeneity of TME, but the
host is immunodeficient [6]. In contrast, autochthonous
or genetically engineered animals develop tumors that are
initiated within the native environment and progress with
an intact TME thereby engaging essential responses. In
parallel, syngeneic models taking cancer and stromal cells
derived from the same genetic background at orthotopic
sites allow co-evolution of the tumor and nearby micro-
environment, thus demonstrating significant efficacy for
preclinical studies (Figure 2).Figure 2 Illustrative models for the preclinical evaluation of novel an
1 (singular), tumors develop in transgenic mice before the preclinical admi
agent. Dramatic cancer resistance is observed in such a therapeutic approa
contrast to route 1, an updated regime incorporating the novel agents (sm
program, which allows targeting both the tumor and TME. Significant disea
much higher preclinical index achieved. (C) Route 3 (singular), tumors deve
cancer cells and stromal cells from the same genetic and/or strain backgro
outcome is observed. (D) Route 4 (combinational), tumors develop in the x
components. Once receiving the same treatments as in Route B, animals p
and D, the preclinical paradigm in prospective trials exclude PDX, althoughConclusions and future directions
Tumors evolve in a complex, dynamic, and functionally
multifaceted microenvironment, which they rely upon for
sustained growth, invasion, and metastasis. Unlike cancer
cells, stromal populations within the TME are genetically
stable, and thus represent an attractive therapeutic target
with minimal risk of treatment resistance and disease re-
lapse. TME-oriented research is increasingly encouraged
and advocated, including the endeavors made in basic,
clinical, and translational medicine. In such an exciting
era of TME biology, experimental data have led to new
scientific concepts and identified novel therapeutic targets
to control the TME-related pathologies. However, there are
not only major advances but daunting challenges, the latter
including how to uncover and restrain susceptible nodes inticancer regimes that incorporate TME-targeting agents. (A) Route
nistration of chemotherapy or targeted therapy is applied as a singular
ch, with only limited efficacy available. (B) Route 2 (combinational), in
all molecule inhibitor or monoclonal antibodies) into the treatment
se regression follows after several cycles of the novel treatments, with
lop in the immunocompetent (wild type) mice xenografted with
und as the host. Upon exposure to treatments as in Route A, a low
enograft mice as in C, harboring implanted cancer and stromal
resent significantly improved therapeutic efficacy. (Note, in routes C
it is a highly recommended model for many cancer studies).
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system. Given that key signaling pathways frequently cross-
talk and mutually interact in an intricate network, insights
into how to solve the tortuous maze in a wider landscape
and how tumor type-specific TMEs may respond differently
to current standard-of-care therapies remain as important is-
sues to tackle with intelligence. Fortunately, with the wealth
of data accumulated so far, we now have a roadmap to con-
vert these challenges into opportunities. For instance, when
defining predictive markers that will eventually aid in the se-
lection of patients who most likely benefit from intervention,
analysis based on the entire TME is an essential step of ut-
most importance to determine specific therapies to employ
[17,103,104]. To this end, gene expression profiling has been
proposed as predictive for response to a given therapy, while
in the coming years a panel of markers will become available
to achieve the predicted goal. More importantly, cancer cell-
directed agents should be combined with the TME-targeting
therapies as it is increasingly clear that stromal cells modu-
late the efficacy of a broad range of standard chemotherapies
and targeted agents. Last but not least, manipulating a dys-
functional TME is critical and will yield striking results in
cancer prevention, pathological control, and disease remis-
sion, as evidenced by the recent success of multiple pilot
trials in clinical oncology.
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